Literature DB >> 26998605

Continuous Venovenous Hemodiafiltration in the Treatment of Maple Syrup Urine Disease.

Demet Demirkol1, Güntülü Şık, Nilüfer Topal, Agop Çıtak, Çigdem Zeybek, Abdülhamit Tüten, Ilmay Bilge.   

Abstract

BACKGROUND: The study aims to define the efficacy of continuous renal replacement therapy in acute metabolic decompensation treatment of maple syrup urine disease (MSUD).
METHODS: All the neonates, infants and children who have had life threatening conditions due to MSUD and were treated with continuous venovenous hemodiafiltration (CVVHDF) were analyzed retrospectively.
RESULTS: Fourteen patients underwent 15 sessions of CVVHDF (age range 15 days to 87 months, mean 40.8 ± 31.4 months). One patient required additional CVVHDF 1 week after cessation of CVVHDF. Twenty seven percent (n = 4) of the patients were intubated and mechanically ventilated. Twelve patients responded to treatment and dramatic neurological improvement was observed within 24 h. Two of the 14 patients required 36 h of CVVHDF for neurological improvement. The mean duration of CVVHDF was 20.2 ± 8.6 (9-36) h. The mean leucine level was 1,648 ± 623.8 (714-2,768) μmol/l before and was 256.5 ± 150.6 (117-646) μmol/l at the end of treatment. No mortality was observed.
CONCLUSION: Continuous hemodiafiltration is an effective and safe method in correcting metabolic disturbances in MSUD.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26998605     DOI: 10.1159/000443783

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  2 in total

1.  Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.

Authors:  Fatma Tuba Eminoğlu; Ümmühan Öncül; Fevzi Kahveci; Emel Okulu; Elvis Kraja; Engin Köse; Tanıl Kendirli
Journal:  Pediatr Nephrol       Date:  2021-10-25       Impact factor: 3.651

2.  Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease.

Authors:  Paula Sánchez-Pintos; Silvia Meavilla; María Goretti López-Ramos; Ángeles García-Cazorla; Maria L Couce
Journal:  Front Pediatr       Date:  2022-08-15       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.